Latest Memorial Sloan–Kettering Cancer Center Stories
A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.
A unique collaboration among physician-scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) has yielded the most comprehensive genomic analysis of prostate cancer to date.
NEW YORK, April 21 /PRNewswire/ -- The Kristen Ann Carr Fund has awarded a grant to Jonathan Lewis, MD, PhD, Chief Executive Officer and Chief Medical Officer of ZIOPHARM Oncology, Inc., which will fund translational work at the Memorial Sloan-Kettering Cancer Center and the Albert Einstein College of Medicine in New York City, for the development of a novel treatment for pediatric sarcoma.
An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer.
PHILADELPHIA, April 7 /PRNewswire/ -- The Sidney Kimmel Foundation for Cancer Research has selected fifteen scientists from across the United States to receive two-year grants under the Foundation's on-going Kimmel Scholar program.
HACKENSACK, N.J., April 5 /PRNewswire/ -- John Theurer Cancer Center at Hackensack University Medical Center will bring together top neuro-oncologists from around the country for a symposium to address new treatment updates and review management of complex cases across a broad array of neuro-oncology specialties.
Nearly half of colon cancer patients will develop liver metastases; the majority will not be candidates for surgeryâ€”interventional radiology treatment destroys cancer locally, extends life.
A Perspective piece in the New England Journal of Medicine calls for change in the way researchers and pharmaceutical companies collect and report adverse symptom information in clinical trials submitted to the Food and Drug Administration (FDA), and how the FDA represents this information on drug labels.
BETHPAGE, N.Y., March 2 /PRNewswire/ -- The Lustgarten Foundation announced today that it has formed a national pancreatic cancer research consortium, a collaborative effort involving six world-renowned medical institutions to advance the most promising research initiatives aimed at finding a cure for pancreatic cancer.
Annual Fundraising Event To Be Held At Roseland Ballroom In New York City On April 18(th) NEW YORK, Jan. 19 /PRNewswire-USNewswire/ -- The T.J.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.